Skip to content
Trifluoperazine
Stelazine (trifluoperazine) is a small molecule pharmaceutical. Trifluoperazine was first approved as Stelazine on 1982-01-01. It is used to treat anxiety disorders, psychotic disorders, and schizophrenia in the USA. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target D(4) dopamine receptor, 5-hydroxytryptamine receptor 2C, histamine H1 receptor, and 5-hydroxytryptamine receptor 2A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trifluoperazine hydrochloride
Tradename
Company
Number
Date
Products
STELAZINEGSKN-011552 DISCN1982-01-01
6 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
trifluoperazine hydrochlorideANDA2022-12-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
anxiety disordersEFO_0006788D001008F41.1
psychotic disorders—D011618F20.81
schizophreniaEFO_0000692D012559F20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AB: Phenothiazines with piperazine structure, antipsychotics
— N05AB06: Trifluoperazine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRIFLUOPERAZINE
INNtrifluoperazine
Description
Trifluoperazine is a member of the class of phenothiazines that is phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position. It has a role as a dopaminergic antagonist, an antiemetic, an EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor, an EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor, a calmodulin antagonist and a phenothiazine antipsychotic drug. It is a N-alkylpiperazine, a N-methylpiperazine, a member of phenothiazines and an organofluorine compound.
Classification
Small molecule
Drug classTypical antipsychotic
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
Identifiers
PDB1LIN
CAS-ID117-89-5
RxCUI10800
ChEMBL IDCHEMBL422
ChEBI ID45951
PubChem CID5566
DrugBankDB00831
UNII ID214IZI85K3 (ChemIDplus, GSRS)
Target
Agency Approved
DRD2
DRD2
Organism
Homo sapiens
Gene name
DRD2
Gene synonyms
NCBI Gene ID
1813
Protein name
D(2) dopamine receptor
Protein synonyms
Dopamine D2 receptor, seven transmembrane helix receptor
Uniprot ID
Q9UPA9
Mouse ortholog
Drd2 (13489)
D(2) dopamine receptor (Q0VGH9)
Alternate
DRD4
DRD4
HTR2C
HTR2C
HRH1
HRH1
HTR2A
HTR2A
Organism
Homo sapiens
Gene name
DRD4
Gene synonyms
NCBI Gene ID
1815
Protein name
D(4) dopamine receptor
Protein synonyms
D(2C) dopamine receptor, Dopamine D4 receptor, seven transmembrane helix receptor
Uniprot ID
Q8NGM5
Mouse ortholog
Drd4 (13491)
D(4) dopamine receptor (Q8BXS4)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,813 documents
View more details
Safety
Black-box Warning
Black-box warning for: Trifluoperazine hydrochloride
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details